Introduction
Promyelocytic leukemia protein (PML), first identified for its oncogenic translocation the retinoic acid receptor α in acute promyelocytic leukemia, is a tumor suppressor with diverse activities in cell growth, cell death, stress responses, or senescence [1] [2] [3] [4] .
Alternative splicing of the human PML gene produces seven PML isoforms (PML I-VII), all of which possess the same N-terminal region composed of RBCC domains connecting to different C-terminal sequences 5, 6 . With the exception of PML-VII, all other PML isoforms contain the nuclear localization sequence. PML-I, with a nuclear exclusion signal, is situated both in the nucleus and cytoplasm 6 . Most of the physiological functions of PML are attributed to PML nuclear bodies 1, 2, 4, 7 . A few activities have been identified with the cytoplasmic form of PML. For example, cytoplasmic PML participates in TGF-β signaling and inhibits p53 function 8, 9 . A cytoplasmic PML mutant enhances the suppressive activity of PML-RARα on RA-mediated transcription 10 . In addition, cytoplasmic PML inhibits herpes simplex virus-1 infection 11 . More recently, PML was found to also localize at the ER and mitochondria-associated membranes (MAM) 12 , contributing to apoptosis induction. The function of cytoplasmic PML remains incompletely characterized.
The NACHT domain-, leucine-rich repeat-, and pyrin domain-containing protein 3
(NLRP3, also known as NALP3 or cryopyrin) inflammasome is activated by a variety of agents including pathogens, microbial products, and environmental and endogenous danger signals [13] [14] [15] [16] [17] [18] . Inappropriate activation of NLRP3 inflammasome leads to a variety of
For personal use only. on . by guest www.bloodjournal.org From 4 autoinflammatory diseases due to overproduction of IL-1β [19] [20] [21] . The assembly of the NLRP3 inflammasome is dependent on two sequential signals. The first inflammatory signal, through NF-κB activation, promotes the expression of pro-IL-1β and NLRP3 22 . The second activation signal stimulates the formation of the NLRP3 inflammasome, presumably by initial reversal of the self-inhibitory association of LRR, followed by the binding of NLRP3
to apoptosis-associated speck-like protein containing a CARD domain (ASC) and procaspase-1. The successful formation of inflammation generates caspase-1, which is essential for the cleavage of pro-IL-1β and pro-IL-18 to produce mature IL-1β and IL-18.
Exactly how the assembly of the NLRP3 inflammasome is triggered remains largely elusive 13, 14, 16, 18 . The difficulties to characterize the biochemical processes underlying inflammasome formation could be partly attributed to the fact that cell lysis induces spontaneous inflammasome assembly in vitro as the consequence of cell membrane damage 23 . Reactive oxygen species (ROS), membrane pore formation, intracellular K + reduction, and lysosomal protease cathepsin B have been postulated as triggers of the NLRP3 inflammasome formation 13, 14, 16, 18 .
Recent studies revealed that NLRP3 is co-localized with structures of the ER and mitochondria-associated membranes after inflammasome stimulation 24, 25 . ROS generated by the mitochondrial respiratory chain promotes mitochondrial DNA release and NLRP3 inflammasome activation 24, 25 . ROS production in mitochondria is regulated by the transport of Ca 2+ ions from mitochondria-associated membranes to mitochondria 24 . Interestingly,
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PML forms a complex with the inositol 1,4,5-triphosphate receptor (IP 3 R) and is required for IP 3 R-mediated Ca 2+ release 12 .
In the present study, we found that PML is required for full NLRP3 inflammasome activation. IL-1β production in macrophages was profoundly compromised in the absence of PML. The expression of pro-IL-1β and NLRP3 was independent of PML. Instead, PML is indispensable for NLRP3 inflammasome formation.
We further demonstrated that targeting to PML effectively suppressed IL-1β production, suggesting a novel way to regulate NLRP3 inflammasome.
METHODS
Reagents. Human PML-I cDNA was obtained from GeneCopoeia (Germantown, MD).
Human PML-II, PML-III, PML-IV, and PML-V cDNAs were gifts by Dr. Kun-Sang Chang (M. D. Anderson Cancer Center, Houston, TX). Human PML-VI cDNA was a gift by Dr.
Ron Evans (Salk Institute, San Diego, CA). pCMX-PML-VI∆SUMO, which carries three mutations (K65R, K160R, and K490R), was previously described 26 . PML-I∆SUMO (PMLI-3KR) 27 was a gift of Dr. Ruey-Hwa Chen (Academia Sinica, Taipei, Taiwan).
PMLex1-4, the truncated form contained PML exons 1-4, was generated from PML-VI by PCR and is analogous to PML-VII minus exon7a. PML-I∆NLS was generated by replacing both Lys487 and Lys490 of NLS with Ala using PCR. The primer used was: 5' CCC AGT Cell cultures. Murine bone marrow cells were flushed out from tibias and femurs by cold RMPI medium, and were cultured in complete DMEM medium with 10% FCS (Invitrogen/Life Technologies), 10 mM glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, and 50 μM 2-ME (complete DMEM medium), with additional 20% L929 cell-conditioned medium to generate bone marrow-derived macrophages. The human monocyte cell line THP-1 was cultured in RPMI-1640 medium with the same supplements (complete RPMI medium). PML was knocked down in THP-1 cells using SMARTpool siRNA purchased from Dharmacon (Lafayette, CO), with sequences: 5' GCA ACC AGT CGG TGC GTG A, 5' GGA CAT GCA CGG TTT CCT G, 5' GAG CTC AAG TGC GAC ATC A, and 5' GGA AAG ATG CAG CTG TAT C.
Secretion and measurement of IL-1β. Mouse bone marrow-derived macrophages and peritoneal macrophages were plated in 12-well plates for overnight culture, replaced with fresh medium, and primed with LPS (0.5 μg/ml), Pam3CSK4 (1 μg/ml), or R837 (15 μg/ml) for 4 h, followed by stimulation with ATP (4 mM) for 40 min, or with monosodium urate (MSU, 150 μg/ml) or alum crystals (500 μg/ml) for 4 h. THP-1 cells were primed with PMA (0.5 μg/ml) for 4 h for differentiation into macrophages, replenished with fresh complete For personal use only. on July 15, 2017. by guest www.bloodjournal.org From Preparation of nuclear and cytosolic extracts. Macrophages were washed and lysed with NP-40 buffer (0.25% NP40, 10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl 2 , 1 mM Na 3 VO 4 , 10 mM NaF, protease inhibitor mixture (Roche)) at 0 °C for 4 min. The supernatants collected after centrifuge at 3000 rpm for 4 min on an Eppendorf microfuge were cytosolic extracts. The pellets were resuspended, washed three times at 4 °C, and lysed in RIPA lysis buffer at 0 °C for 30 min. Lysates were centrifuged at 13,200 rpm for 10 min, and supernatants were collected as nuclear extracts. The purity of cytosolic extracts and nucleus were assessed by the exclusive expression of GAPDH and Lamin B, respectively.
In situ proximity ligation assay. In situ proximity ligation assay was conducted as described by Söderberg et al. Mitochondrial DNA release. The release of mitochondrial DNA into cytosol was performed according to Nakahira et al. 25 , with identical quantitative PCR primers for 18S and inflammasome. In addition to caspase-1, generation of active cathepsin B was attenuated in PML-deficient macrophages, whereas the levels of procathepsin B were unchanged ( Fig.   2E ).
RESULTS

Reduced
We observed a similar defect in the human macrophage cell line THP-1. In PMA-primed THP-1 cells, stimulation with nigericin led to the generation of active caspase-1 and mature p17 IL-1β (Supplemental Fig. 3 ). Knockdown of PML by siRNA, not
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From affecting the levels of NLRP3, procaspase-1, and ASC (Supplemental Fig. 3 ), reduced the production of p10 caspase-1 and p17 IL-1β in THP-1 cells, further supporting a role of PML in caspase-1 activation and pro-IL-1β processing.
PML increases IL-1β production in reconstituted NLRP3 inflammasome
We further evaluated the involvement of PML in the reconstituted NLRP3 inflammasome in 293T cells. ASC and NLRP3 are absent in 293T cells, and functional NLRP3 inflammasome could be reconstituted through transfection of plasmids encoding pro-IL-1β, NLRP3, procaspase-1, and ASC. The expression of each transfected gene in 293T cells was confirmed by Western blotting (Fig. 3B) . Co-transfection of pro-IL-1β, procaspase-1, NLRP3, and ASC resulted in the secretion of IL-1β into culture supernatants ( Fig. 3A and 3B ). The strict requirement for the full reconstitution of NLRP3 inflammasome was shown by that little IL-1β was produced in the absence of any components ( Next, the effect of PML on caspase-1 activation and IL-1β generation in reconstituted inflammasome was assessed. PML-I co-transfection led to a clear increase in IL-1β production in the reconstituted NLRP3 inflammasome (Fig. 3A) . PML-I expression did not alter the apparent levels of pro-IL-1β, NLRP3, and procaspase-1 (Fig. 3B) , suggesting an effect of PML-I on the activation of the reconstituted NLRP3 inflammasome. We further tested other PML isoforms for their capacity to promote IL-1β generation. Overexpression of PML-II, PML-III, PML-IV, PML-V, and PML-VI also increased the production of IL-1β
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From 13 in 293T cells with reconstituted NLRP3 inflammasome (Fig. 3C ). In addition, PML-I∆3K (PML-I 3KR 27 ), the mutant that cannot be sumoylated, exerted an additive effect on the generation of IL-1β indistinguishable from wild-type PML-I in the same system (Fig. 3D , ∆ 3K). A similar result in NLRP3 inflammasome activation was found with PML-VI∆3K
when compared with PML-VI (Supplemental Fig. 5 ). Therefore, PML increased IL-1β generation in reconstituted NLRP3 inflammasome independent of PML sumoylation.
We also elucidated whether PML participated in the function of the NLRP3 inflammasome in vivo. To assay for in vivo activation of the NLRP3 inflammasome, PBS alone or MSU crystals were intraperitoneally administered to Pml +/+ and Pml -/-mice, and the influx of neutrophils into the peritoneal cavity as a consequence of IL-1β generation was determined 32, 33 . As shown in Supplemental Figure 6A and 6B, peritoneal infiltration of polymorphonuclear neutrophils (PMN) was significantly reduced in Pml -/-mice as compared
to Pml +/+ mice. Therefore, PML is also required for NLRP3 inflammasome activation in vivo.
PML does not regulate the activation of AIM2 inflammasome
We further examined whether PML was able to promote the activation of other inflammasome. AIM-2 inflammasome is activated by the binding of cytosolic dsDNA [14] [15] [16] [17] [18] .
Transfection of macrophages with dAdT resulted in production of IL-1β, which was not affected by PML deficiency (Fig. 4A ). In addition, expression of PML-I did not add to the activation of the reconstituted AIM2 inflammasome, in contrast to the enhancing effect of PML-I in the reconstituted NLRP3 inflammsome (Fig. 4B) . Therefore, PML does not 
Cytoplasmic PML may contribute to NLRP3 inflammasome activation
Even though PML is mainly located in the nucleus, previous reports have demonstrated the presence of PML in the cytosol 6, [8] [9] [10] [11] [12] . We investigated whether cytosolic PML also contributes to the activation of the NLRP3 inflammasome. We produced PMLI mutant with mutation at NLS (PML-I∆NLS). The predominant cytoplasmic localization of PML-I∆NLS, relative to PML-I, was confirmed by immunofluorescence (Supplemental Fig. 7 ). In reconstituted NLRP3 inflammasome, PML-I∆NLS led to a moderate increase in enhancing IL-1β production relative to the wild-type PML-I (Fig. 3D) . We also generated a truncated PML analogous to PML-VII, the cytosolic form of PML. PMLex1-4 was preferentially expressed in cytoplasm (Supplemental Fig. 7) , and exhibited an enhancing effect like PML-I∆NLS in the activation of reconstituted NLRP3 inflammasome (Fig. 3D) . Results from PML-I∆NLS and PMLex1-4 suggest that cytosolic PML also facilitates NLRP3 inflammasome activation. We detected an elevated level of cytoplasmic PML in LPS-primed macrophages (Fig. 5A) , likely due to an overall increase in PML proteins in macrophages stimulated with LPS ( Fig. 2B-2D ). The enhanced cytoplasmic presence was observed with PML of different molecular weights, suggesting the increase was not limited to a specific PML isoform in the activated macrophages (Fig. 5A ). Co-treatment of macrophages with LPS and alum crystal did not further increase the level of cytoplasmic (Fig. 5A) . LPS-induced cytosolic appearance of PML was attenuated by leptomycin B (Fig. 5B) , suggesting that some of the cytosolic PML is exported from the nucleus. It may be noted that cytoplasmic PML represents a smaller fraction of total cellular PML than nuclear PML. Quantitation analysis by densitometry indicates that 15-20% of total PML was situated in cytoplasm in macrophages.
We also examined whether the reduction of cytosolic PML by leptomycin B affected IL-1β production in macrophages. The addition of leptomycin B for 2 h before alum crystal stimulation suppressed IL-1β secretion in LPS-primed macrophages, while longer incubation with leptomycin B (3 h) led to further inhibition of IL-1β generation (Fig. 5C ). The presence of leptomycin B did not affect the levels of NLRP3, pro-IL-1β, procaspase-1, and ASC in macrophages, but profoundly suppressed the generation of p10 caspase-1 and mature IL-1β (Fig. 5D) . Reduction in cytoplasmic PML decreased caspase-1-dependent IL-1β production, suggesting that cytosolic PML may contribute to NLRP3 inflammasome activation.
We next investigated whether PML is associated with NLRP3. Immunoprecipitation analysis revealed a PML-I-NLRP3 interaction when NLRP3-Myc and PML-I-FLAG were overexpressed in 293T cells (Supplemental Fig. 8A ). We subsequently identified that the LRR domain of NLRP3 interacted with PML-I (Supplemental Fig. 8B ). However, upon examining the binding of other PML isoforms to NLRP3, we did not detect interaction between NLRP3 and PML-II, PML-III, PML-IV, PML-V, and PML-VI (Supplemental Fig.   8C , data not shown for PML-II, PML-III, PML-IV, and PML-V). Therefore, association of NLRP3 with PML is not essential for PML to enhance NLRP3 inflammasome activation. 
PML in NLRP3 inflammasome formation in situ
We also measured the assembly of NLRP3 inflammasome in situ. Proximity ligation assay 28 was used to detect the close association between NLRP3 and ASC upon inflammasome formation. In proximity ligation assay, the in situ interaction between two proteins brings their respective antibody to close proximity, allowing the oligonucleotides linked to the antibodies to prime for circular DNA strands amplification. Consistent with the requirement of dual stimulation by LPS and ATP for NLRP3 inflammasome activation in normal macrophages, no association between NLRP3 and ASC could be detected in untreated macrophages or in macrophages stimulated with LPS alone (Fig. 6A ). NLRP3
became closely proximal to ASC after the addition of ATP to LPS-treated macrophages.
ATP-induced NLRP3-ASC interaction was diminished in LPS-primed PML-deficient macrophages ( Fig. 6A and 6B ), consistent with a requirement of PML for NLRP3 inflammasome formation. Similarly, LPS plus ATP-induced NLRP3-caspase-1 close association was largely eliminated in Pml -/-macrophages ( Fig. 6C and 6D ). The proximity ligation assay was also used to determine the in situ interaction between PML and caspase-1 during inflammasome formation. Similar to the NLRP3-caspase-1 interaction, PML was spatially associated with caspase-1 in macrophages treated with LPS and ATP, but not with LPS alone (Fig. 6E and 6F ). NLRP3 was also brought to close proximity of PML when macrophages were activated by LPS and ATP ( Fig. 6E and 6G ).
Reduced ROS generation and mitochondrial DNA release in PML-null macrophages
PML has been shown to mediate the release of Ca 2+ from the ER 12 , and uptake of Ca
2+
For personal use only. production (Supplemental Fig. 9A ). By contrast, TNF-α generation was not affected by okadaic acid (Supplemental Fig. 9B ). We also investigated whether a deficiency in PML 9D ). Together, these data suggest a possibility that PML deficiency is coupled to decreased mitochondrial ROS production and attenuated mitochondrial DNA release, leading to impaired NLRP3 inflammasome activation.
Downregulation of PML by arsenic oxide suppresses IL-1β production
PML and PML-retinoic acid receptor α fusion protein are effectively degraded by arsenic trioxide 34 . We examined whether arsenic trioxide treatment could be used to suppress inflammation activation. Co-incubation of cells with arsenic trioxide for 1 h was sufficient to eliminate most of PML in THP-1 cells (Fig. 7A) . NLRP3, constitutively expressed in THP-1 cells, and the upregulated pro-IL-1β were not affected by arsenic
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Activation of caspase-1 and generation of IL-1β stimulated by LPS/ATP were largely inhibited in arsenic trioxide-treated macrophages (Fig. 7B and 7C ). In contrast, the induction of NLRP3 and pro-IL-1β was not affected by arsenic trioxide treatment in macrophages (Fig.   7B ). As high concentration of arsenic trioxide is known to trigger apoptosis in many cell types 35 , we also monitored cell viability and found no apparent cell death at the dose and the duration of the experiment (Supplemental Fig. 10A and 10C ). In addition, the production of TNF-α was not affected by the treatment with arsenic trioxide (Fig. 7D, Supplemental Fig.   10B ). Therefore, targeted degradation of PML effectively prevents the activation of NLRP3 inflammasome.
DISCUSSION
In the present study, we illustrate that NLRP3 inflammasome-mediated IL-1β production is severely compromised in the absence of PML. Most of the physiological activities of PML have been associated with PML nuclear body formation 1,2,4 . PML binds directly to many transcription factors and modulates their transcription activities 7, 36 . PML also regulates gene expression by sequestering a transcription repressor into the PML nuclear body 26, 37 . The PML nuclear body is also the major site where post-translational modification
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From and degradation of PML-interacting proteins takes place 4, 38 . We examined the possibility that PML participates in IL-1β expression through transcription regulation and found that the levels of the known NLRP3 components, NLRP3, procaspase-1, ASC, and pro-IL-1β were not affected by PML deficiency. By contrast, the second stage of NLRP3 inflammasome activation, characterized by the formation of the NLRP3 inflammasome, processing of caspase-1, and cleavage of pro-IL-1β, was severely impaired in PML-deficient macrophages.
This was also confirmed by that reconstitution of NLRP3 inflammasome was significantly increased by further co-expression of PML. In addition, the in situ interaction between NLRP3 and ASC was diminished in Pml -/-macrophages. Together, defects in caspase-1 activation and IL-1β production in PML-null macrophages could be attributed to a defective assembly of the NLRP3 inflammasome. Consistent with an involvement of PML in NLRP3 inflammasome activation, PML is expressed at high levels in macrophages 39 . Notably, PML deficiency or PML overexpression did not affect the activation of AIM2 inflammasome (Fig.   4 ), suggesting that PML targets to NLRP3 inflammasome, but not to a common mechanism downstream of different inflammasomes.
We found that all PML isoforms exhibited similar activity in promoting NLRP3
inflammasome assembly (Fig. 5C) . A PML-VII analog PMLex1-4 was as effectively as PML-I in enhancing NLRP3 inflammasome formation (Fig. 5D) , suggesting the N-terminal region of PML encoded by exons 1-4, shared by all PML isoforms, is sufficient to facilitate NLRP3 inflammasome activation. This is in contrast to the reported association of distinct inflammasome activation. In the present study, we found that inhibition of PP2a by okadaic acid decreased IL-1β production, PML-deficiency impaired mitochondrial ROS production and reduced mitochondrial DNA release (Supplemental Fig. 9 ). PML may thus contribute to NLRP3 inflammasome activation at stages prior to ROS production and mitochondrial DNA release 12, 24, 25 . Further studies will be required to establish the biochemical coupling from PML, Ca 2+ release, ROS production, to NLRP3 inflammasome activation.
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The exact biochemical processes involved in NLRP3 inflammasome activation remain incompletely understood. K + efflux, ROS, and cathepsin B are a few non-mutually exclusive mediators involved in inflammasome activation 13, 14, 16, 18 . Notably, PML deficiency also impaired release of cathepsin B (Fig. 2E) , revealing an essential role of PML in both ROS production and cathepsin B activation. This is in contrast to disruption of autophage proteins that affects only ROS generation but not cathepsin B release 25 . The observed enhancing function of PML in NLRP3 inflammasome is likely due to a combination of both ROS-dependent and ROS-independent pathways. It may be noted that PML is involved in the post-translational modification, sequestration, or degradation of the nuclear-body (NB)-associated proteins 4, 38 . Even though we have shown that sumoylation mutant of PML-I and PML-VI promoted NLRP3 inflammation ( Fig. 3D and Supplemental Fig. 5 ), we cannot exclude the possibility that some PML-partners modified at NB enter cytoplasm and participates in the NLRP3 inflammasome formation. We are in the progress to delineate the complete mechanisms on how PML promotes NLRP3 inflammamsome assembly.
NLRP3 Inflammasome activation is implicated in diseases including familial cold autoinflammatory syndrome, gout, silicosis, asbestosis, and type 2 diabetes mellitus [19] [20] [21] .
IL-1β and IL-18 also regulate a wide variety of lymphocyte functions, including T cell costimulation, production of Th2 response, and generation of Th17 responses 41, 42 .
Consequently, excess IL-1β contributes to the development of allergic and inflammatory
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diseases. Anti-inflammatory compounds, such as agents to block IL-1β activity or suppress caspase-1, have been developed to counteract inflammasome-and IL-1β -associated diseases 43 . Our results demonstrate that PML is involved in NLRP3 inflammasome activation, and down-regulation of PML helps reduce inflammasome-mediated pathogenesis.
PML is likely another viable target for therapy against NLRP3 inflammasome-mediated diseases. This is supported by that arsenic trioxide, the well-known PML antagonist, suppressed MSU-induced IL-1 production (Fig. 7) . Arsenic oxide has been successfully used to reduce IL-18 levels 44 . Even though arsenic oxide exhibits multiple actions 35 , some of the effects are likely due to PML degradation. These results suggest the potential application to control inflammasome-associated diseases by downregulation of PML expression.
Further investigation to develop reagent specific targeting to PML may help delineate such possibility.
For BMDMs were treated with LPS and ATP, stained with anti-PML (H-238, rabbit pAb) and anti-NLRP3, or anti-PML and anti-caspase-1, and the association of PML to caspase-1 or NLRP3 was measured (E) and quantified (F, G). Bar indicates 10 μm. *P < 0.05, **P < 0.01 for paired t-test. 
